Eli Lilly 'Clear Leader in Obesity' Drugs, UBS Says; Raises 2025 Earnings Forecast

MT Newswires Live

Jun 27, 2025

Eli Lilly (LLY) is "a clear leader in obesity" and is in a good position to see its market share grow in Q2 due to its diabetes and obesity drug pipeline, according to analysts at UBS.

In a note to clients Friday, UBS analysts said investors in the pharmaceutical giant are "bracing for a 3Q impact" when CVS Caremark updates the list of prescription drugs covered by its insurance plans in July. The analysts said CVS prefers Wegovy made by Novo Nordisk (NVO) for certain plans.

UBS raised its forecast for Eli Lilly's full-year 2025 revenue and EPS. It now expects revenue of $60.6 billion, compared with its previous estimate of $59.4 billion, and EPS of $22.21 from $21.83.

UBS maintained its buy rating and $1,050 price target on Eli Lilly's stock.

Price: 798.90, Change: +3.78, Percent Change: +0.48

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2546744595"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546744595\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546744595?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-27 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546744595","market":"sh","top_or_hot":-1,"title":"Eli Lilly 'Clear Leader in Obesity' Drugs, UBS Says; Raises 2025 Earnings Forecast","media":"MT Newswires Live","content":"<html><body><p> Eli Lilly (LLY) is \"a clear leader in obesity\" and is in a good position to see its market share grow in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> due to its diabetes and obesity drug pipeline, according to analysts at UBS.</p><p>In a note to clients Friday, UBS analysts said investors in the pharmaceutical giant are \"bracing for a 3Q impact\" when CVS Caremark updates the list of prescription drugs covered by its insurance plans in July. The analysts said CVS prefers Wegovy made by Novo Nordisk (NVO) for certain plans.</p><p>UBS raised its forecast for Eli Lilly's full-year 2025 revenue and EPS. It now expects revenue of $60.6 billion, compared with its previous estimate of $59.4 billion, and EPS of $22.21 from $21.83.</p><p>UBS maintained its buy rating and $1,050 price target on Eli Lilly's stock.</p><p>Price: 798.90, Change: +3.78, Percent Change: +0.48</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly 'Clear Leader in Obesity' Drugs, UBS Says; Raises 2025 Earnings Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly 'Clear Leader in Obesity' Drugs, UBS Says; Raises 2025 Earnings Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-27 22:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Eli Lilly (LLY) is \"a clear leader in obesity\" and is in a good position to see its market share grow in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> due to its diabetes and obesity drug pipeline, according to analysts at UBS.</p><p>In a note to clients Friday, UBS analysts said investors in the pharmaceutical giant are \"bracing for a 3Q impact\" when CVS Caremark updates the list of prescription drugs covered by its insurance plans in July. The analysts said CVS prefers Wegovy made by Novo Nordisk (NVO) for certain plans.</p><p>UBS raised its forecast for Eli Lilly's full-year 2025 revenue and EPS. It now expects revenue of $60.6 billion, compared with its previous estimate of $59.4 billion, and EPS of $22.21 from $21.83.</p><p>UBS maintained its buy rating and $1,050 price target on Eli Lilly's stock.</p><p>Price: 798.90, Change: +3.78, Percent Change: +0.48</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2546744595","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546744595","pubTimestamp":1751033297,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eli Lilly  is \"a clear leader in obesity\" and is in a good position to see its market share grow in Q2 due to its diabetes and obesity drug pipeline, according to analysts at UBS.In a note to clients Friday, UBS analysts said investors in the pharmaceutical giant are \"bracing for a 3Q impact\" when CVS Caremark updates the list of prescription drugs covered by its insurance plans in July. The analysts said CVS prefers Wegovy made by Novo Nordisk  for certain plans.UBS raised its forecast for Eli Lilly's full-year 2025 revenue and EPS. It now expects revenue of $60.6 billion, compared with its previous estimate of $59.4 billion, and EPS of $22.21 from $21.83.UBS maintained its buy rating and $1,050 price target on Eli Lilly's stock.Price: 798.90, Change: +3.78, Percent Change: +0.48","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"瑞银表示，礼来公司是“肥胖药物领域的明显领导者”；上调2025年盈利预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"Eli Lilly (LLY) is \"a clear leader in obesity\" and is in a good position to see its market share grow in Q2 due to its diabetes and obesity drug pipeline, according to analysts at UBS.In a note to clients Friday, UBS analysts said investors in the pharmaceutical giant are \"bracing for a 3Q impact\" when CVS Caremark updates the list of prescription drugs covered by its insurance plans in July. The analysts said CVS prefers Wegovy made by Novo Nordisk (NVO) for certain plans.UBS raised its forecast for Eli Lilly's full-year 2025 revenue and EPS. It now expects revenue of $60.6 billion, compared with its previous estimate of $59.4 billion, and EPS of $22.21 from $21.83.UBS maintained its buy rating and $1,050 price target on Eli Lilly's stock.Price: 798.90, Change: +3.78, Percent Change: +0.48","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}